An Open Label Randomized, Single Dose, Three-way, Partial Replicate Bioequivalence Study to Determine the Bioequivalence of Solifenacin Succinate & Mirabegron From Mirfenacin MR 5/50 mg Extended Release Tablets (Hikma Pharma, Egypt) Versus Vesicare 5 mg Film Coated Tablets & Betmiga 50 mg Prolonged-Release Tablets (Astellas Pharma Europe B.V, the Netherlands / Astellas Pharma Europe B.V, the Netherlands)
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- For Mirabegron: AUC0→t
研究概览
简要总结
An open label randomized, single dose, three-way, partial replicate bioequivalence study to determine the bioequivalence of Solifenacin Succinate & Mirabegron From Mirfenacin MR 5/50 mg Extended Release Tablets (Hikma Pharma, Egypt) Versus Vesicare 5 mg Film Coated Tablets & Betmiga 50 mg Prolonged-Release Tablets (Astellas Pharma Europe B.V, the Netherlands / Astellas Pharma Europe B.V, the Netherlands)
详细描述
Healthy volunteers, 18-55 years of age, selected from the Egyptian population fulfilling the selection criteria. 30 Healthy volunteers (28 volunteers + 2 extra volunteers to compensate for drop-outs) will participate in the study. All dosed subject samples will be analyzed and their data will be included in the final study report.
For Solifenacin:
Primary Pharmacokinetic Parameters: Cmax and truncated AUC0→72 Secondary Pharmacokinetic Parameters: Tmax
For Mirabegron:
Primary Pharmacokinetic Parameters: Cmax, AUC0→t and AUC0→∞ Secondary Pharmacokinetic Parameters: Ke, tmax and t1/2e. ANOVA using 5% significance level for log transformed (with the 90% confidence intervals), untransformed data of Cmax, AUC0→t and AUC0→∞ and for untransformed data of Ke, tmax and t1/2e, for Mirabegron and untransformed data of Cmax and truncated AUC0→t and for untransformed data of tmax for Solifenacin.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male or female, age 18 to 55 years, inclusive.
- •Body weight within 15% of normal range (18.5-30.0) according to the accepted normal values for body mass index (BMI).
- •Medical demographics without evidence of clinically significant deviation from normal medical condition, eg.: no history of heart, liver, kidney, gastrointestinal, nervous system, or metabolic abnormalities.
- •Results of clinical laboratory test are within the normal range or with a deviation that is not considered clinically significant by principal investigator.
- •Females should be on a suitable birth control method.
- •Fully informed subjects that consented to participate in the study.
排除标准
- •Subjects with known allergy to the products tested.
- •Subjects who meet any of the contraindications to the administration of Solifenacin succinate and/or Mirabegron.
- •Subject does not agree not to consume any medication or food which may affect CYP3A4 enzyme at least two weeks prior to first study drug administration until donating the last sample of the study.
- •Subjects that do not agree not to consume alcohol-containing beverages and foods for 2 weeks before dosing and throughout the period of sample collection.
- •Heavy smokers.
- •Female subjects who were pregnant or nursing.
- •Acute infection within one week preceding first study drug administration.
- •History of drug or alcohol abuse.
- •Subject does not comply with the stated instruction of not taking any prescription or non-prescription drugs within two weeks before first study drug administration and until the end of the study.
- •Subject is on a special diet (for example subject is vegetarian).
- •Subject does not agree not to consume any beverages or foods containing methyl-xanthenes e.g. caffeine (coffee, tea, cola, chocolate etc.) 48 hours prior to the study administration of either study period until donating the last sample in each respective period.
- •Subject does not agree not to consume any beverages or foods containing grapefruit 14 days prior to first study drug administration until the end of the study.
- •Subject has a family history of severe diseases which have direct impact on the study.
- •Participation in a bioequivalence study or in a clinical study within the last 8 weeks before first study drug administration.
- •Subject intends to be hospitalized within 3 months after first study drug administration.
- •Subjects who have blood donated or lost more than 500 mL blood within 3 months prior to the study.
研究组 & 干预措施
R reference (first dose)
Reference drugs (Vesicare & Betmiga)
干预措施: Vesicare (Solifenacin Succinate 5 mg) & Betmiga (Mirabegron 50 mg) (Reference first dose) (Drug)
T test
Test drug (Mirfenacin MR)
干预措施: Mirfenacin MR (Solifenacin Succinate 5 mg & Mirabegron 50 mg) (Test) (Drug)
R reference (second dose)
Reference drugs (Vesicare & Betmiga)
干预措施: Vesicare (Solifenacin Succinate 5 mg) & Betmiga (Mirabegron 50 mg) (Reference second dose) (Drug)
结局指标
主要结局
For Mirabegron: AUC0→t
时间窗: Up to 240 hours post dose in each treatment period
to measure the area under the curve from zero time to 240 hours
For Mirabegron: AUC0→∞
时间窗: Up to 240 hours post dose in each treatment period
to measure the area under the curve from zero time to infinity
For Solifenacin: Cmax
时间窗: Up to 72 hours post dose in each treatment period
to measure the maximal measured plasma concentration
For Solifenacin: truncated AUC0→72
时间窗: Up to 72 hours post dose in each treatment period
to measure truncated area under the curve from zero time to 72 hours
For Mirabegron: Cmax
时间窗: Up to 240 hours post dose in each treatment period
to measure the maximal measured plasma concentration
次要结局
- For Solifenacin & Mirabegron: Tmax(For Solifenacin:Up to 72 hours post dose in each treatment period & For Mirabegron:Up to 240 hours post dose in each treatment period)